AstraZeneca PLCAZNNASDAQ
Loading
Revenue Growth Under PressureDecelerating
Percentile Rank54
3Y CAGR+0.1%
5Y CAGR-30.5%
Year-over-Year Change
Year-over-year revenue growth rate
3Y CAGR
+0.1%/yr
vs -38.6%/yr prior
5Y CAGR
-30.5%/yr
Recent acceleration
Acceleration
+38.7pp
Accelerating
Percentile
P54
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 2.05% |
| Q3 2025 | 5.08% |
| Q2 2025 | 6.40% |
| Q1 2025 | -8.75% |
| Q4 2024 | 9.78% |
| Q3 2024 | 4.85% |
| Q2 2024 | 2.04% |
| Q1 2024 | 5.45% |
| Q4 2023 | 4.63% |
| Q3 2023 | 0.67% |
| Q2 2023 | 4.94% |
| Q1 2023 | -2.93% |
| Q4 2022 | 2.05% |
| Q3 2022 | 1.96% |
| Q2 2022 | -5.43% |
| Q1 2022 | -5.17% |
| Q4 2021 | 21.74% |
| Q3 2021 | 20.02% |
| Q2 2021 | 12.30% |
| Q1 2021 | -1.21% |
| Q4 2020 | 12.65% |
| Q3 2020 | 4.83% |
| Q2 2020 | -1.24% |
| Q1 2020 | -4.65% |
| Q4 2019 | 4.03% |
| Q3 2019 | 10.01% |
| Q2 2019 | 6.05% |
| Q1 2019 | -14.43% |
| Q4 2018 | 20.17% |
| Q3 2018 | 3.59% |
| Q2 2018 | -0.44% |
| Q1 2018 | -10.37% |
| Q4 2017 | -7.30% |
| Q3 2017 | 23.38% |
| Q2 2017 | -6.55% |
| Q1 2017 | -3.22% |
| Q4 2016 | -2.00% |
| Q3 2016 | 1.71% |
| Q2 2016 | -8.37% |
| Q1 2016 | -4.44% |